艾伯维Abbvie Inc (ABBV) 2017年年度报告「NYSE」.pdf

1、We di dnt come t hi s f ar,t o only come t hi s f ar2017 Annual Repor t on For m 10-K 2018 Not i ce of Annual Meet i ng&Proxy St at ementAbout AbbVi e AbbVi e i s a global,research-dri ven bi opharmaceut i cal company commi t t ed t o developi ng i nnovat i ve advanced t herapi es f or some of t he

2、worlds most complex and cri t i cal condi t i ons.The companys mi ssi on i s t o use i t s expert i se,dedi cat ed people and uni que approach t o i nnovat i on t o markedly i mprove t reat ment s across f our pri mary t herapeut i c areas:i mmunology,oncology,vi rology and neurosci ence.In more t h

3、an 75 count ri es,AbbVi e employees are worki ng every day t o advance healt h solut i ons f or people around t he world.For more i nf ormat i on about AbbVi e,please vi si t us at www.abbvi .13NOV2012213657664DEC201212233206Dear AbbVie Stockholder,2017 marked our fifth year as AbbVie and proved to

4、be our most successful year since we launched in 2013.AbbVie has come a long way since those early days as a new biopharmaceutical company,but our focus anddedication to develop innovative new therapies while delivering top-tier performance endures.However,we didn tcome this far,to only come this fa

5、r.The transformation we have made into a high performing biopharmaceuticalcompany positions us well to continue to deliver outstanding performance.Our performance since inception has been nothing short of remarkable with a consistent track record of revenueand adjusted earnings growth at or near the

6、 top of our peer group,whether you measure that by our 2017,three-year or five-year performance.Since our inception,we ve generated significant stockholder value with a totalreturn of nearly 240 percent,more than double that of the S&P 500 Index and number one in our peer group.In 2017,we delivered